secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006084
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q4 core lung diag revenue $8.2M (+51% YoY); guides 2023 total rev $52-55M
--------------------------------------------------------------------------------

- Total revenue Q4 $9.6M, FY2022 $38.2M; core lung diagnostic revenue $29.3M (+57% YoY).
- Net loss Q4 $20.3M, FY2022 $65.4M; includes $7.0M loss on debt extinguishment/modification.
- Cash and equivalents $43.1M at Dec 31, 2022; raised $65.7M net from debt/equity in Q4.
- 2023 total revenue guidance $52-55M, representing 36-44% growth over 2022 total revenue.
- Biopharma services revenue $3.7M in FY2022 (-34% YoY); highest dollars under contract entering 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/0000950170-23-006084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023006084/bdsx-20230306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer